Uncover key drivers, emerging technologies, and competitive movements shaping the remote visualization workstations market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Breast Cancer Liquid Biopsy Market be in 2030 compared with 2026?

The breast cancer liquid biopsy market has expanded rapidly in recent years. It is projected to increase from $0.89 billion in 2025 to $1.02 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.6%. This historical growth can be linked to factors such as the rising incidence of breast cancer, the drawbacks of tissue biopsy, progress in oncology diagnostics, enhanced awareness of screening, and the broadening of laboratory testing.

The breast cancer liquid biopsy market size is projected to experience substantial expansion in the coming years, anticipated to reach $1.75 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.3%. This growth during the forecast period is primarily driven by the increasing adoption of precision oncology, advancements in AI-based mutation analysis, the development of personalized treatment planning, the rising prevalence of cfDNA testing, and the expansion of decentralized cancer diagnostics. Key trends influencing the market in this period include multi-biomarker blood-based testing, the emergence of non-invasive cancer monitoring, enhanced treatment response tracking, improved early recurrence detection, and the growth of personalized oncology diagnostics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

What Drivers Are Guiding Growth Patterns In The Breast Cancer Liquid Biopsy Market?

The increasing prevalence of breast cancer cases is projected to stimulate the growth of the breast cancer liquid biopsy market moving forward. Breast cancer is a malignancy that develops in the cells of the breast, typically found in the lobules, which are milk-producing glands, or the ducts that transport milk to the nipple. The rise in breast cancer cases can be attributed to several factors, including genetic predisposition, hormonal imbalances, an aging population, lifestyle changes, obesity, alcohol consumption, insufficient physical activity, exposure to radiation, and various environmental pollutants. During treatment, a breast cancer liquid biopsy is utilized to detect circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, facilitating real-time monitoring of the disease. This method is beneficial for assessing treatment response, identifying resistance to therapies, and pinpointing genetic mutations for targeted interventions. For instance, data from the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, indicates that the number of new breast cancer cases is anticipated to climb to 319,750 in 2025, rising from 313,510 cases in 2024. Therefore, the upward trend in breast cancer cases is a significant factor driving the growth of the breast cancer liquid biopsy market.

Which Segments Are Driving Activity In The Breast Cancer Liquid Biopsy Market?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

What Trends Are Projected To Support The Growth Of The Breast Cancer Liquid Biopsy Market?

Leading firms within the breast cancer liquid biopsy market are prioritizing the creation of novel products, including companion diagnostics, to facilitate tailored treatment strategies by pinpointing individuals likely to respond to particular therapies. These companion diagnostics leverage liquid biopsy techniques to identify biomarkers like genetic mutations, circulating tumor DNA (ctDNA), or protein expressions that signal responsiveness to treatment. As an illustration, in January 2023, Guardant Health Inc., a US-based biotechnology company, obtained Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test. This test functions as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), a therapy designed for advanced or metastatic breast cancer patients exhibiting ESR1 mutations. This authorization allows oncologists to employ the test for comprehensive genomic profiling, thereby identifying patients who could benefit from the specific targeted therapy. This represents Guardant Health’s first U.S. Food and Drug Administration (FDA) approval within the breast cancer field, thereby enhancing its contribution to precision oncology.

Which Major Firms Are Strengthening Their Position In The Breast Cancer Liquid Biopsy Market?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Breast Cancer Liquid Biopsy Market?

North America was the largest region in the breast cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Breast Cancer Liquid Biopsy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Liquid Biopsy Market 2026, By The Business Research Company

Liquid Biopsy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Breast Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Biopsy Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.